For the quarter ending 2026-03-31, TRVI had $498K increase in cash & cash equivalents over the period. -$16,791K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Chronic cough in ipf clinical trial expense | - | 7,992 | - | - |
| Refractory chronic cough clinical trial expense | - | 1,457 | - | - |
| Other clinical trials and studies | - | 6,219 | - | - |
| Chronic cough in ipf clinical trial expense | - | - | 822 | - |
| Clinical trial material | - | 1,827 | - | - |
| Refractory chronic cough clinical trial expense | - | - | 119 | - |
| Other clinical development expenses | - | 5,942 | - | - |
| Clinical trial material | - | - | 5,058 | - |
| Employee compensation (excluding stock compensation expense) | - | 11,820 | - | - |
| Other clinical trials and studies | - | - | 27 | - |
| Other clinical development expenses | - | - | 1,548 | - |
| Employee compensation (excluding stock compensation expense) | - | - | 3,041 | - |
| Stock-based compensation expense | - | - | 1,243 | - |
| Stock compensation expense | - | 5,185 | - | - |
| Other segment items | - | 2,335 | 6,518 | - |
| Interest income, net | - | 1,903 | 4,633 | - |
| Net loss | -13,192 | -8,316 | -11,802 | -22,641 |
| Stock-based compensation | 2,191 | 1,350 | 1,243 | 2,592 |
| Operating lease right-of-use assets | 105 | 107 | 108 | 222 |
| Depreciation and amortization | 34 | 31 | 38 | 75 |
| Accretion of available-for-sale marketable securities, net | 431 | 562 | 298 | 778 |
| Write off of deferred offering costs | - | 26 | - | - |
| Accrued expenses and other liabilities | -1,075 | -555 | 143 | -1,003 |
| Loss on disposal of property, equipment and leasehold improvements | - | -7 | - | - |
| Accounts payable | -1,483 | 123 | -282 | -439 |
| Prepaid expenses and other current assets | 2,838 | -158 | 30 | 1,606 |
| Net cash used in operating activities | -16,689 | -7,631 | -10,880 | -23,578 |
| Proceeds from disgorgement of beneficial owner's short-swing profits | - | 0 | 725 | - |
| Proceeds from maturities of available-for-sale marketable securities | 25,552 | 23,788 | 20,684 | 32,095 |
| Proceeds from employee stock purchase plan | - | 59 | 0 | 59 |
| Purchases of available-for-sale marketable securities | 8,485 | 54,396 | 71,610 | 44,656 |
| Payments of offering costs | - | 0 | 219 | 590 |
| Purchases of property, equipment and leasehold improvements | 102 | 0 | 12 | 0 |
| Payments of finance lease | - | 0 | 0 | 11 |
| Net cash provided by (used in) investing activities | 16,965 | -30,608 | -50,938 | -12,561 |
| Proceeds from offering of common stock, net of commissions | - | - | 0 | 108,154 |
| Proceeds from offering, net of commissions | - | 108,154 | - | - |
| Proceeds from exercises of warrants | - | 0 | 0 | 10,757 |
| Proceeds from at-the-market sales agreement, net of commissions and allocated fees | - | - | 0 | 0 |
| Proceeds from exercises of stock options | 222 | 225 | 1,123 | 731 |
| Net cash provided by financing activities | 222 | 284 | 1,629 | 119,100 |
| Net increase (decrease) in cash and cash equivalents | 498 | -37,955 | -60,189 | 82,961 |
| Cash and cash equivalents at beginning of period | 18,914 | 56,869 | 34,097 | - |
| Cash and cash equivalents at end of period | 19,412 | 18,914 | 56,869 | - |
Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc. (TRVI)